Brought to you by 
VCs buy commercial lab business of Genoptix from Novartis
21 Aug 2020
Executive Summary
Ampersand Capital and 1315 Capital have acquired Genoptix Inc. (clinical oncology diagnostics and informatics services) from Novartis AG for an undisclosed sum. The acquisition primarily includes Genoptix's commercial laboratory business; the firm's biopharma business was retained by Novartis and will operate as a new legal entity named Navigate Biopharma Services. Novartis originally purchased Genoptix for $440mm in 2011.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
VCs buy commercial lab business of Genoptix from Novartis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice